sclerosis is the hardening or induration of a tissue, vessel, or organ, most often resulting from replacement of normal parenchymal cells with dense fibrous (collagenous) connective tissue. It differs from fibrosis, which describes the excess deposition of fibrous tissue itself (the process), while sclerosis describes the resulting hardened, thickened tissue state — the two terms overlap heavily in practice and are frequently used interchangeably in documentation. The underlying mechanism typically involves chronic injury, inflammation, or ischemia that triggers fibroblast proliferation and excessive collagen synthesis, progressively stiffening the affected structure and impairing its normal function. sclerosis is almost always pathological, though minor age-related tissue stiffening is sometimes described physiologically (e.g., arterial stiffening with normal aging, distinct from frank atherosclerosis). Clinically significant subtypes span nearly every organ system: otosclerosis (abnormal bone remodeling of the otic capsule causing conductive hearing loss; H80.00), scleritis (inflammatory scleral induration of the eye; H15.001), systemic sclerosis (autoimmune fibrosis of skin and internal organs; M34.9), multiple sclerosis (demyelinating CNS plaques; G35.-), and atherosclerosis (lipid-driven arterial wall hardening; I70.90). It is most commonly confused with fibrosis (process vs. resulting hardened state) and atrophy (sclerosis involves tissue thickening/hardening from added connective tissue, while atrophy is a reduction or wasting of tissue mass).
Noun-forming suffix — “condition, process, or abnormal state of”
The word entered English in the 1680s as a direct medical borrowing from Latin sclerosis, itself from Greek sklērōsis (σκλήρωσις) — literally “a hardening.” The root sklēros (“hard”) connects sclerosis to the entire -scler- root family: sclera (the tough, hard outer coat of the eyeball — literally “the hard one”), scleroderma (skler- + derma “skin” → “hard skin”), and arteriosclerosis (arterio- + sclerosis → “hardening of the arteries”). The combining form scler- is highly productive in medical terminology, appearing in scleritis, episcleritis, sclerotherapy, otosclerosis, and nephrosclerosis.
🔀 ALIASES / ALTERNATE TERMS
Sclerotic(adjective form — e.g., “sclerotic bone changes,” “sclerotic vessel wall,” “sclerotic plaques”)
Sclerosed(adjective/past-participle form — describes a vessel or tissue that has already undergone sclerosis, e.g., “sclerosed hemorrhoidal vessel” post-sclerotherapy)
Induration(clinical synonym; used broadly for any area of hardened tissue on exam, not always specific to fibrotic sclerosis — e.g., “indurated plaque” in Peyronie disease)
Hardening(lay term; commonly used by patients and in patient-facing materials, especially for arteriosclerosis/atherosclerosis)
🔗 RELATED TERMS
fibrosis — closely related process term describing excess fibrous connective tissue deposition; sclerosis describes the resulting hardened tissue state, fibrosis describes the depositional process itself; the two are often used interchangeably in clinical documentation
atrophy — near-opposite process; atrophy is a reduction in tissue mass/size, while sclerosis is a hardening/thickening from added connective tissue
induration — general clinical descriptor for firm, hardened tissue on palpation; broader than sclerosis and not always fibrotic in origin
otosclerosis — abnormal bony remodeling of the otic capsule/stapes footplate causing progressive conductive (and sometimes mixed) hearing loss; H80.00-H80.93
Required on otosclerosis (stapedectomy) and scleral repair claims for laterality; bilateral otosclerosis surgery is typically staged (second ear ≥6 months later), so -50 is rarely used here
Increased procedural services — e.g., revision stapedectomy with dense obliterative otosclerosis or extensive Peyronie plaque excision requiring extended graft work
⚠️ Coding Note: Laterality is mandatory to the full 6th-character specificity for H80 (otosclerosis) and H15.0 (scleritis) families — “otosclerosis, unspecified ear” or “scleritis NOS” without laterality risks denial when the operative note or exam clearly documents a side. Stapedectomy (69660-69662) carries a 90-day global period; postoperative visits for dizziness or hearing checks within that window are bundled and should not be billed separately without modifier -24/-79 as appropriate. For systemic sclerosis, sequence the organ-manifestation code (e.g., M34.81 with lung involvement) first when a specific manifestation is documented, and add the corresponding manifestation code (e.g., J84.- for interstitial lung disease) — undercoding to M34.9 alone when a manifestation is clearly documented (“scleroderma with ILD,” “sclerodactyly with dyspnea”) is a common inpatient profee miss. For G35.D (multiple sclerosis), this is a high-weight CMS-HCC category (HCC 78) — code at every encounter where MS is being actively managed or monitored, even without an acute flare; watch for the documentation trigger phrases “demyelinating disease” or “relapsing-remitting” that should prompt querying for the specific G35 code rather than a vague neurologic symptom code. For atherosclerosis (I70), full specificity of laterality and severity (claudication vs. rest pain vs. ulceration vs. gangrene) materially changes HCC/RAF weighting — “PAD” or “peripheral vascular disease” documented alone without severity detail is a frequent undercoding trigger warranting a query. For hypertensive nephrosclerosis, per ICD-10-CM combination code guidelines, I12.0/I12.9 must be sequenced with the causal relationship to CKD assumed (hypertension + CKD = code to I12 category), paired with the appropriate N18.- stage code as a secondary/additional code — do not code hypertension and CKD separately as unrelated conditions. For N48.6 (Peyronie disease), payers frequently require prior authorization and documented curvature severity (degrees) for collagenase injection (CPT 54205) medical necessity.